SCHEMBL10044002

SCHEMBL10044002

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1-c1cc2cnc(-c3ccccc3)cc2n(C)c1=O

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.70
KDR P35968 3/20 0.55
MAPK14 Q16539 3/20 0.55
LCK P06239 2/20 0.55
JAK3 P52333 2/20 0.55
TEK Q02763 2/20 0.55
DDR2 Q16832 1/20 0.54
RAF1 P04049 12/20 0.53
BRAF P15056 12/20 0.53
KIT P10721 2/20 0.51
MAPK13 O15264 1/20 0.51
LYN P07948 1/20 0.51
PDGFRA P16234 1/20 0.51
MAPK12 P53778 1/20 0.51
EPHB4 P54760 1/20 0.51
EPHA4 P54764 1/20 0.51
MAPK11 Q15759 1/20 0.51
ABL1 P00519 1/20 0.51
CSF1R P07333 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10044003 0.91 SYK (0.67) SYKKDRMAPK14LCKJAK3
SCHEMBL10043698 0.89 SYK (0.70) SYKKDRMAPK14LCKJAK3
SCHEMBL4400805 0.88 SYK (0.69) SYKKDRMAPK14LCKJAK3
SCHEMBL5046392 0.88 SYK (0.69) SYKKDRMAPK14LCKJAK3
SCHEMBL10043998 0.88 SYK (0.62) SYKKDRMAPK14LCKJAK3
SCHEMBL14011539 0.87 SYK (0.68) SYKKDRMAPK14LCKJAK3
SCHEMBL10072197 0.86 SYK (0.67) SYKKDRMAPK14LCKJAK3
SCHEMBL10043786 0.86 SYK (0.66) SYKKDRMAPK14LCKJAK3
SCHEMBL5046656 0.86 SYK (0.66) SYKKDRMAPK14LCKJAK3
SCHEMBL502335 0.85 SYK (0.65) SYKKDRMAPK14LCKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed
WO-2008051757-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885KDR 108/4885MAPK14 117/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885KDR 108/4885MAPK14 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.